Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Ocumension Therapeutics
PSD Bank Rhein-Ruhr eG
Press Release ------------------------------------------------------------------------------- Nicox Highlights Positive NCX 470 Phase 3 Data Confirming Therapeutic Profile at the 2026 American Glaucoma Society Annual Meeting ------------------------------------------------------------------------------- February 24, 2026 - release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that positive...
PSD Bank Rhein-Ruhr eG
Press Release ------------------------------------------------------------------------------- Nicox Announces Positive Feedback from pre-NDA Meeting with U.S. FDA for NCX 470 ------------------------------------------------------------------------------- * U.S. NDA submission on track for summer 2026 * Nicox to receive milestone payment from Kowa upon submission of the NDA * NDA submission based on Phase 3 clinical data showing NCX 470 lowered intraocular pressure by up to 10mmHg in patients...
PSD Bank Rhein-Ruhr eG
Press Release ------------------------------------------------------------------------------- Nicox to Present Data from NCX 470 Phase 3 Studies at American Glaucoma Society (AGS) Annual Meeting 2026 ------------------------------------------------------------------------------- February 10, 2026 - release at 7:30 am Sophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that phase 3 clinical study results,...
PSD Bank Rhein-Ruhr eG
Press Release ------------------------------------------------------------------------------- Nicox Announces Conference Attendance in H1 2026 and Upcoming Scientific Data Presentations ------------------------------------------------------------------------------- January 20, 2026 - release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced participation in several key ophthalmology, financial...
PSD Bank Rhein-Ruhr eG
Press Release ------------------------------------------------------------------------------- Nicox Completes NCX 470 New Drug Application Key Data Generation for Submission as Planned in H1 2026 ------------------------------------------------------------------------------- * All clinical trial and long-term stability data required for the preparation of the New Drug Applications (NDA) has been generated and analysed * Pre-NDA meeting(1) with the U.S. Food and Drug Administration (FDA) in...
PSD Bank Rhein-Ruhr eG
Press Release ------------------------------------------------------------------------------- Nicox Provides First Half 2025 Financial Results ------------------------------------------------------------------------------- * New Drug Application (NDA) submissions for NCX 470 expected in 2026 in the U.S. and China * Company believes that it can finance its existing operations for at least 12 months and expects to fully repay existing financial debts in 2026 October 23, 2025 - release at 7:30...
PSD Bank Rhein-Ruhr eG
Press Release ------------------------------------------------------------------------------- Nicox Announces Shareholder Q&A Webpage Available ------------------------------------------------------------------------------- August 26, 2025 - release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that a new webpage "Q&A" is available on the company's website, www.nicox.com...
PSD Bank Rhein-Ruhr eG
Press Release ------------------------------------------------------------------------------- Nicox Expects to Fully Repay Financial Debts with NCX 470 De-Risked and Globally Licensed ------------------------------------------------------------------------------- * Company expects to fully repay existing financial debts in 2026 * NCX 470 NDA submissions in U.S. (H1 2026) and subsequently in China * Milestones payable on U.S. NDA submission and on approval * Glaukos extends NCX 1728 research...
PSD Bank Rhein-Ruhr eG
Press Release ------------------------------------------------------------------------------- Nicox's NCX 470 Demonstrates Sustained Efficacy through 12 Months in Denali Clinical Trial with no new Safety Observations ------------------------------------------------------------------------------- * Additional pre-planned analysis of the NCX 470 Denali trial completed * NCX 470 maintains robust intraocular pressure lowering at 6, 9 and 12 months * Other analyses broadly in line with the trends...
Nicox Provides Second Quarter 2023 Financial and Business Highlights
Nicox Provides Second Quarter 2023 Financial and Business Highlights Today 1:30 AM ET (Thomson Reuters ONE)Print Press Release Nicox Provides Second Quarter 2023 Financial and Business Highlights - Net revenue1 of EUR0.9 million for the second quarter of 2023 - Cash position of EUR19.0 million, with a 12-month cash runway, as of June 30, 2023 - NCX 470 Denali Phase 3 clinical trial 55% randomized July 19, 2023 - release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Paris:...
Nicox Estimates Potential Annual Global Net Sales for NCX 470 of over $300 million
Nicox Estimates Potential Annual Global Net Sales for NCX 470 of over $300 million Today 1:30 AM ET (Thomson Reuters ONE)Print Press Release Nicox Estimates Potential Annual Global Net Sales for NCX 470 of over $300 million - NCX 470 therapeutic profile positively received among U.S. eye care professionals in a market survey conducted with a leading, independent research agency - Potential annual global net sales for NCX 470 estimated to reach at least $300 million within 8 years from the...
Nicox Presented NCX 470 Phase 3 Mont Blanc Adaptive Design Data and Additional Subset Analysis Showing Superiority over Latanoprost at the World Glaucoma Congress
Nicox Presented NCX 470 Phase 3 Mont Blanc Adaptive Design Data and Additional Subset Analysis Showing Superiority over Latanoprost at the World Glaucoma Congress Today 1:30 AM ET (Thomson Reuters ONE)Print Press Release Nicox Presented NCX 470 Phase 3 Mont Blanc Adaptive Design Data and Additional Subset Analysis Showing Superiority over Latanoprost at the World Glaucoma Congress - NCX 470 0.1% showed up to 1.73mmHg greater mean diurnal intraocular pressure (IOP) reduction from baseline than...
Ocumension Releases its 2022 Interim Report with its core product Youshiying® being approved for marketing, continuously accelerating product commercialization - PR Newswire APAC
, /PRNewswire/ -- On August 26, 2022 (Beijing time), Ocumension Therapeutics (1477.HK) released its 2022 interim report. The Company's overall performance remained remarkable despite the fact that the pandemic caused considerable trouble in commercializing its ophthalmic products in the first half of the year.
Ocumension OT-401 (Product name: YUTIO), a treatment for chronic non-infectious uveitis officially approved for marketing by the National Medical Products Administration - PR Newswire APAC
BEIJING, June 23, 2022 /PRNewswire/ -- Ocumension Therapeutics （1477.HK）announced that the New Drug Application (NDA) for the core product in its pipeline, OT-401 (Sterile non-bioerodible intravitreal implant, Product name: YUTIO), was officially approved by the National Pharmaceutical Administration (NMPA) for the treatment of chronic non-infectious uveitis involving the posterior segment of the eye (chronic NIU-PS).
Ocumension Therapeutics: Annual Results Announcement For The Year Ended December 31, 2020
HONG KONG SAR - Media OutReach[1] - 22 March 2021 - The Board of Directors of the Company is pleased to announce the audited consolidated annual results of the Group for the year ended December 31, 2020, together with the comparative figures for year ended December 31, 2019 as follows. These consolidated financial statements of the Group for the Reporting Period have been reviewed by the Audit Committee and audited by the Company's auditors, Deloitte Touche Tohmatsu.
Ocumension Therapeutics (1477.HK) Reports Revenue Growth in 2020, National Commercial Construction has been started to become outstanding
HONG KONG, March 20, 2021 /PRNewswire/ -- The Chinese ophthalmology platform company, Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, the "Group" ), (stock code: 1477.HK), announced its annual results for the year ended 31 December 2020 today. Ocumension Therapeutics handed over its first brilliant annual report since its listing.
Ocumension Therapeutics: Annual Results Announcement For The Year Ended December 31, 2020
By Ocumension Therapeutics, Media OutReach 2021/03/22 16:15 HONG KONG SAR - Media OutReach - 22 March 2021 - The Board of Directors of the Company is pleased to announce the audited consolidated annual results of the Group for the year ended December 31, 2020, together with the comparative figures for year ended December 31, 2019 as follows.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Ocumension
Contact Ocumension, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack